BRONS + TEN KATE 1/26/22 BRONS + TEN KATE 1/26/22

VectorY and Wageningen University sign strategic collaboration for the development of novel baculovirus-based AAV production technologies

Read More

BRONS + TEN KATE 8/17/21 BRONS + TEN KATE 8/17/21

Assembling a new gene therapy company to develop the next generation of pioneering medicines

Read More

BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21

VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders

Read More

BRONS + TEN KATE 6/15/21 BRONS + TEN KATE 6/15/21

VectorY strengthens leadership with appointments of new CEO and CTO

Read More

BRONS + TEN KATE 5/21/21 BRONS + TEN KATE 5/21/21

VectorY presents at ASGCT 2021 about advances and challenges of vectorized antibodies for the treatment of neuromuscular diseases.

Read More

BRONS + TEN KATE 4/13/21 BRONS + TEN KATE 4/13/21

VectorY have been selected as winners of the Merck Millipore 2021 European Advance Biotech Program!

Read More

BRONS + TEN KATE 2/10/21 BRONS + TEN KATE 2/10/21

Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies

Read More